Details for Patent: 7,713,938
✉ Email this page to a colleague
Which drugs does patent 7,713,938 protect, and when does it expire?
Patent 7,713,938 protects SYNJARDY XR, TRIJARDY XR, GLYXAMBI, JARDIANCE, and SYNJARDY, and is included in five NDAs.
Protection for SYNJARDY XR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-one patent family members in thirty-two countries.
Summary for Patent: 7,713,938
Title: | Crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy- )-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
Abstract: | The invention relates to a crystalline form of 1-chloro-4-(.beta.-D-glucopyranos-1-yl)-2-[4-((S) -tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments. |
Inventor(s): | Himmelsbach; Frank (Mittelbiberach, DE), Schmid; Sandra (Bad Wurzach, DE), Schuehle; Martin (Oberhoefen, DE), Martin; Hans-Jurgen (Biberach, DE), Eckhardt; Matthias (Biberach, DE) |
Assignee: | Boehringer Ingelheim International GmbH (Ingelheim, DE) |
Application Number: | 11/406,971 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,713,938 |
Patent Claim Types: see list of patent claims | Compound; Composition; Use; Formulation; |
Drugs Protected by US Patent 7,713,938
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-001 | Dec 9, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-002 | Dec 9, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Boehringer Ingelheim | SYNJARDY XR | empagliflozin; metformin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 208658-003 | Dec 9, 2016 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,713,938
International Family Members for US Patent 7,713,938
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 053720 | ⤷ Try a Trial | |||
Argentina | 087208 | ⤷ Try a Trial | |||
Austria | E452883 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |